Skip to main content
  • Register
  • Help
  • Contact us

Enveric Biosciences Inc (ENVB) USD0.01

Sell:$2.26 Buy:$2.27 Change: $0.09 (4.09%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Change: $0.09 (4.09%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Change: $0.09 (4.09%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Enveric Biosciences Inc., formerly AMERI Holdings, Inc., is a patient-central biotechnology company. The Company is focused on enhancing lives of people affected by the side effects of cancer treatments, such as radiodermatitis and chemotherapy-induced peripheral neuropathy. The Company is engaged in leveraging its clinical developments derived from cannabinoids and taps into its global network of scientists and oncology physicians. The Company is advancing its pipeline of new-generation of naturally occurring and synthetic compounds. It is developing product candidates that target skin-related ailments common among cancer patients, including radiodermatitis, pruritus, rashes and dry skin, as well as indications such as chemotherapy-induced peripheral neuropathy, with future areas of focus that may include depression, pain and anxiety.

Contact details

4851 Tamiami Trail N, Suite 200
United States
+1 (239) 3021707

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$51.20 million
Shares in issue:
21.88 million
United States
US dollar

Key personnel

  • David Johnson
    Chairman of the Board, Chief Executive Officer
  • John Van Buiten
    Chief Financial Officer
  • Carter Ward
    Chief Financial Officer
  • Avani Kanubaddi
    Chief Operating Officer
  • Robert Wilkins
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.